Takara Bio USA, Inc RetroNectin® GMP grade reagent
ID: 24-002687Type: Presolicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH - CCBETHESDA, MD, 20892, USA

PSC

IN VITRO DIAGNOSTIC SUBSTANCES, REAGENTS, TEST KITS AND SETS (6550)

Original Source

https://sam.gov/opp/b3b91922ab37470b913796e67f343fd0/view
Timeline
    Description

    Presolicitation HEALTH AND HUMAN SERVICES, DEPARTMENT OF NATIONAL INSTITUTES OF HEALTH is planning to procure Takara Bio USA, Inc RetroNectin® GMP grade reagent. This reagent is typically used in the development, evaluation, and validation of investigational new drugs (INDs) for cellular therapies and the manufacture of cellular therapy products for approved clinical trials. The Center of Cellular Engineering, an AABB accredited cellular therapy laboratory, intends to purchase 30 vials of RetroNectin® GMP grade reagent from Takara Bio USA, Inc. The reagent will be used in the manufacturing process of clinical T-cells for the treatment of NIH CC patients with various medical conditions. The acquisition will be conducted using simplified acquisition procedures, and interested parties may submit their capabilities and interest in response to this notice. The closing date for submissions is December 23, 2023, at 12:00 pm EST.

    Point(s) of Contact
    Sheri Eiri
    000000000
    sheri.eiri@nih.gov
    Files
    No associated files provided.
    Lifecycle
    Title
    Type
    Takara Bio USA, Inc RetroNectin® GMP grade reagent
    Currently viewing
    Presolicitation
    Similar Opportunities
    Notice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD)
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to 10X Genomics, Inc. for the procurement of specialized reagents necessary for a research project focused on the immune response to Pneumocystis infection. The required products include proprietary kits such as the Chromium Single Cell Mouse BCR Amplification Kit and the GEM-X Universal 5' Gene Expression v3, which are essential for isolating and amplifying RNA and chromatin-accessible regions from individual cells, ensuring experimental accuracy and data integrity. Interested parties capable of providing similar products may submit a capability statement by June 15, 2025, to Tasha Lowe at lowet2@mail.nih.gov, as the procurement will follow the Simplified Acquisition Procedures under FAR Part 13.
    Notice of Intent to Sole Source for 10X Genomics, Inc. Reagents Department (CCMD)
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to award a sole source contract to 10X Genomics, Inc. for the procurement of specialized reagents necessary for a critical research project on the effects of SARS-CoV-2 on human brain tissues. The required products include proprietary kits such as the Dual Index Kit TS Set A and GEM-X Flex Gene Expression Kits, which are essential for isolating and amplifying RNA at the single-cell level, and are uniquely suited for the NIH's modified protocols compliant with Biosafety Level 3 requirements. This acquisition is crucial for maintaining the continuity of research and patient care, as any substitutions could lead to significant delays and require extensive re-validation. Interested parties capable of providing similar products may submit a capability statement to Tasha Lowe at lowet2@mail.nih.gov by June 21, 2025, at 3:00 PM EST.
    Reagents for The Olink® Signature Q100 system
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), intends to procure reagents for the Olink® Signature Q100 system used by its Critical Care Medicine Department (CCMD) in Bethesda, Maryland. The procurement involves a sole source purchase from Olink Proteomics Inc. for specific reagents essential for studying protein biomarkers in patient samples, as only Olink's products are compatible with the system and critical for ongoing research. Interested parties capable of providing similar products may submit a capability statement by June 20, 2025, to Tasha Lowe at lowet2@mail.nih.gov, as this acquisition is being conducted under simplified acquisition procedures with no set-aside for competition.
    10X Genomics, Inc. Reagents for the Critical Care Medicine Department (CCMD)
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to procure reagents from 10X Genomics, Inc. for the Critical Care Medicine Department (CCMD) as part of a project focused on the Early Detection of Lung Diseases (EDLI). The procurement includes specific items such as the Chromium Next GEM Chip K Single Cell Kit and various amplification kits, which are essential for high-resolution gene expression profiling and immune repertoire analysis. This acquisition is critical to ensure the continuity and integrity of ongoing research, as only proprietary reagents from 10X Genomics are compatible with existing NIH equipment. Interested parties capable of providing similar products may submit a capability statement by June 16, 2025, to Tasha Lowe at lowet2@mail.nih.gov.
    Illumina Reagents and Consumables
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Heart, Lung, and Blood Institute (NHLBI), intends to negotiate a contract modification with Illumina, Inc. for the supply of proprietary reagents and consumables essential for the operation of Illumina sequencing and genotyping systems utilized by the NIH Intramural Sequencing Center (NISC). This modification is critical to ensure the continuous availability of high-quality, brand-name supplies necessary for ongoing genomic research projects, which play a vital role in diagnosing diseases and developing new therapies. The contract extension will prolong the period of performance from September 3, 2020, to March 2, 2026, and while interested parties may express their capabilities, this is not a solicitation for proposals, as the government retains the right to pursue competitive options if necessary. For further inquiries, interested parties can contact Ethan J. Mueller at ethan.mueller@nih.gov or Dorothy L. Maxwell at dorothy.maxwell@nih.gov.
    Notice of Intent to Sole Source
    Buyer not available
    The Department of Health and Human Services, specifically the FDA, intends to award a Sole Source Firm Fixed Price contract to Fujifilm Irvine Scientific, Inc. for the procurement of Human Induced Pluripotent Stem Cell-Derived (hiPSC) cells. The objective of this contract is to acquire specific types of hiPSC cells, including cardiomyocytes, neurons, astrocytes, and hepatocytes, which are essential for supporting research on microphysiological systems (MPS) crucial for drug safety and efficacy evaluations. This procurement underscores the FDA's commitment to enhancing drug evaluation processes through innovative biological models, with a contract period of one year from the award date. Interested parties who believe they can meet the requirements are invited to submit capability statements by June 16, 2025, to the primary contact, Rodney D. Aytch, at rodney.aytch@fda.hhs.gov.
    6640--Notice of Intent to Sole Source - One Lambda Inc. Reagents -
    Buyer not available
    The Department of Veterans Affairs (VA) intends to enter into a Sole Source contract with One Lambda Inc. for the procurement of molecular SSO typing reagents necessary for HLA testing pertinent to donor-recipient transplantation at the VA Iowa City Health Care System. This contract will be established on an Indefinite Delivery/Indefinite Quantity (IDIQ) basis, covering the fiscal years 2026 to 2031, and emphasizes the unique compatibility of these reagents with existing systems and regulatory standards mandated by the American Society of Histocompatibility & Immunogenetics (ASHI). Interested vendors may express their interest and demonstrate their capability to meet the requirements; however, the government may proceed with the sole-source approach if no suitable alternatives are presented. Responses must be submitted by June 27, 2025, to Dennis Salmonsen at dennis.salmonsen@va.gov.
    Gore Medical branded stents (Brand Name restriction)
    Buyer not available
    The Department of Health and Human Services, National Institutes of Health seeks to procure specific medical devices for use in interventional radiology procedures. These are brand-restricted items, with the National Institute of Health specifying Gore Medical branded stents. The scope of work involves supplying several variants of two medical devices: Viatorr Tips Endo CX and Viabahn BX Balloon Expander Endo. The Viatorr Tips are measured in millimeters and vary in length, while the Viabahn BX Balloon Expanders are used in catheterization procedures. The medical devices are intended for minimally invasive procedures. The bill of materials provided outlines the exact models and quantities sought. Offerors must provide the following: 1 unit of Model PTB8105275, ID 00733132635016 - 8-10mmX5cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model PTB8107275, ID 00733132635030 - 8-10mmX7cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model PTB8108275, ID 00733132635047 - 8-10mmX8cm/2cm 10Fr VIATORR TIPS ENDO CX 1 unit of Model BXB083901A, ID 00733132658718 - 8MMX39MM 7Fr 80CM Cath RP VIABAHN BX BALLOON EXP ENDO 1 unit of Model BXB085901A, ID 00733132658732 - 8MMX59MM 7Fr 80CM Cath RP VIABAHN BX BALLOON EXP ENDO Eligible applicants should be well-established surgical and medical instrument manufacturers (NAICS code 339112) with the ability to deliver the specified devices promptly. The evaluation of quotes will consider technical capability, price, and past performance. Quotes should be submitted to Lu Chang at lu-chang.lu@nih.gov by 5:00 PM EST on 08/01/2024, including the RFQ number (RFQ-CC-24-010258) in the subject line. Further inquiries can be directed to the same email address. This opportunity is a combined synopsis and solicitation issued under FAR Subpart 12.6. The resulting contract will be a firm fixed-price order.
    Maintenance Agreement for FACSymphony A5 Cell Analyzer
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking a contractor to provide a Maintenance Agreement for the FACSymphony A5 Cell Analyzer and associated components. This procurement involves a one-year full-service agreement that includes preventive maintenance, unlimited service visits, and technical support for critical laboratory equipment used in research, ensuring operational efficiency and minimizing downtime. The contract is set to run from June 24, 2025, to June 23, 2026, with a sole source award anticipated to BD Biosciences, the original manufacturer, due to proprietary service requirements. Interested parties must submit their quotations by June 17, 2025, to Tina Robinson at robinsti@mail.nih.gov, referencing solicitation number 75N94025Q00073.
    Service Contract for LSR Fortessa X-20 Cell Sorters
    Buyer not available
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking to award a service contract for the maintenance of LSR Fortessa X-20 Cell Sorters. The contract will cover a one-year preventative maintenance agreement for two BD Biosciences LSR Fortessa X-20 Cell Analyzers, including travel, parts, and labor for maintenance and repairs, as well as regular upkeep of the lasers essential for flow cytometry. This equipment is critical for the NIH's research in hematopoiesis and lymphocyte biology, ensuring optimal performance and accuracy in isolating cell groups by their fluorescent tags. Interested parties must submit their capability statements and proposals by June 15, 2025, with the contract value expected to be under $250,000. For further inquiries, contact Michael Falzone at falzoneml@nih.gov.